Trials / Active Not Recruiting
Active Not RecruitingNCT05949619
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M02D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib: To explore the safety and preliminary efficacy of BL-M02D1 to further define RP2D in a variety of solid tumors such as locally advanced or metastatic non-small cell lung cancer. Phase II: To explore the efficacy of BL-M02D1 using single-agent RP2D obtained from phase I clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-M02D1 | Administration by intravenous infusion |
Timeline
- Start date
- 2023-09-04
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2023-07-18
- Last updated
- 2025-09-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05949619. Inclusion in this directory is not an endorsement.